IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9839688 B1

PDFFull Text
Date of Patent:
Dec. 12, 2017

Filed:

Jun. 24, 2015

Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

Applicants:

Provectus Pharmaceuticals, Inc., Knoxville, TN (US);

Pfizer, Inc., New York, NY (US);

Inventors:

Craig J. Eagle, New York, NY (US);

H. Craig Dees, Knoxville, TN (US);

Eric A. Wachter, Oak Ridge, TN (US);

Jamie Singer, Knoxville, TN (US);

Assignees:

Provectus Pharmatech, Inc., Knoxville, TN (US);

Pfizer, Inc., New York, NY (US);

Attorney:

Husch Blackwell LLP

Primary Examiner:

Elly-Gerald Stoica

Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/35 (2006.01); A61K 38/21 (2006.01); C07K 16/30 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 31/352 (2006.01); A61K 31/365 (2006.01); A61K 39/245 (2006.01); A61K 47/02 (2006.01); C12N 7/00 (2006.01); A61K 45/06 (2006.01); A61K 47/60 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/352 (2013.01); A61K 31/365 (2013.01); A61K 38/193 (2013.01); A61K 38/20 (2013.01); A61K 38/204 (2013.01); A61K 38/2006 (2013.01); A61K 38/2013 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 38/217 (2013.01); A61K 39/0005 (2013.01); A61K 39/0011 (2013.01); A61K 39/245 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/60 (2017.08); C07K 16/30 (2013.01); C12N 7/00 (2013.01); A61K 2039/505 (2013.01); C12N 2710/16021 (2013.01); C12N 2710/16034 (2013.01);
Abstract

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.

Find Patent Forward Citations

Loading…